logo
Share SHARE
FONT-SIZE Plus   Neg

Medical Properties Trust Q1 Normalized FFO Increases, But Misses View

Real estate investment trust Medical Properties Trust, Inc, (MPW) Friday reported an increase in first-quarter normalized funds from operations, or FFO, but below analysts' expectations. The company's net income and revenues for the period registered a growth compared to last year.

For the three month period, the company reported normalized FFO of $34.8 million or $0.25 per share, compared with $22.5 million or $0.18 per share during corresponding quarter last year. On average, ten analysts polled by Thomson Reuters expected $0.26 per share for the quarter. Analysts' estimates typically exclude one-time items.

The company recorded net income of $26.2 million or $0.18 per share, compared with $10.6 million or $0.08 per share for the same quarter last year.

The firm generated revenues of $58.4 million, a 42 percent increase from $41.3 million reported last year. The Street expected the company to record revenues of $59.4 million for the quarter.

The Company expects to realize a gain on sale of property of approximately $2.1 million in the second quarter of 2013. The Company continues to believe that acquisition volume and timing, along with current capital market conditions, will generate Normalized FFO per share of $1.10. Analyst expect the company to report $1.10 per share for the year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Foodservice distributor Sysco Corp. (SYY) reported a third-quarter profit that grew 22.7 percent from last year, while quarterly sales increased 2.2 percent. Both earnings per share and revenue for the quarter beat analysts' expectations. Halliburton Co. (HAL) and Baker Hughes Inc. (BHI) announced Sunday that they terminated the merger agreement they entered into in November 2014, effective April 30, 2016. In connection with the termination of the merger agreement, Halliburton will pay Baker Hughes the termination fee of $3.5 billion... The bench to bedside journey of drugs is fraught with challenges. It is estimated that only 5 in 5,000 compounds that enter preclinical testing make it to human testing, and out of those 5, only 1 may pass through all the regulatory hurdles needed to reach pharmacy shelves.
comments powered by Disqus
Follow RTT